Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting

被引:1
作者
Yousuf, Sanobia [1 ]
Ahmedani, Muhammad Yakoob [2 ,3 ]
机构
[1] Baqai Med Univ, Baqai Inst Diabetol & Endocrinol, Res Dept, Karachi, Pakistan
[2] Baqai Med Univ, Baqai Inst Diabetol & Endocrinol, Karachi, Pakistan
[3] Plot 1-2, 2-B,Nazimabad 2, Karachi 74600, Pakistan
关键词
Ramadan fasting; type2 diabetes mellitus; Empagliflozin; Complications; SGLT2; INHIBITORS; CANAGLIFLOZIN; TOLERABILITY; MANAGEMENT; SULFONYLUREA; OUTCOMES;
D O I
10.1016/j.dsx.2022.102633
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: To explore efficacy and safety of empagliflozin in people with type2 diabetes during Ramadan fasting Methods: People with type2 diabetes (T2DM) who were taking empagliflozin and sulphonylurea with or without a metformin and dipeptidyl peptidase inhibitors (DPP4) recruited a month before Ramadan. Glycated hemoglobin (HbA1c) and estimated glomerular filtration rate (eGFR) were recorded pre- and post-Ramadan. A predesigned diary was given to the participants to keep track of their T2DM status during Ramadan. The proportion of the people who had hypoglycaemia, or any adverse event related to the study drug was assessed after-Ramadan. Results: A total of 116 participants completed the study. Symptomatic episodes of hypoglycaemia were more common among people who used sulphonylurea (i.e., 8.6%). Genitourinary infections and volume depletion events were recorded more in people on empagliflozin i.e., (6.9% and 5.17%, respectively). A significant reduction in body mass index (BMI), and HbA1c was noted among people on empagliflozin post Ramadan. A significant reduction in eGFR was noted only in people who were taking empagliflozin in combination with metformin. Conclusion: Empagliflozin was found to be safe and effective in fasting people with T2DM. Further largescale studies are needed to validate our findings. (c) 2022 Published by Elsevier Ltd on behalf of Diabetes India.
引用
收藏
页数:5
相关论文
共 26 条
[1]   Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes [J].
Abdelgadir, Elamin ;
Rashid, Fauzia ;
Bashier, Alaaeldin ;
Al Saeed, Maryam ;
Khalifa, Azza ;
Alawadi, Fatheya ;
Hassanein, Mohamed .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (05) :2927-2932
[2]   A prospective multi-country observational trial to compare the incidences of diabetic ketoacidosis in the month of Ramadan, the preceding month, and the following month (DKAR international) [J].
Abdelgadir E.I.E. ;
Hassanein M.M. ;
Bashier A.M.K. ;
Abdelaziz S. ;
Baki S. ;
Chadli A. ;
Askaoui S. ;
Nawal E.A. ;
Slim I.S. ;
Ghizlane E.M. ;
Hafidh K. ;
Alawadi F. .
Journal of Diabetes & Metabolic Disorders, 15 (1)
[3]   Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies [J].
Abdelrahim, Dana ;
Faris, MoezAlIslam E. ;
Hassanein, Mohamed ;
Shakir, Ayman Z. ;
Yusuf, Ayesha M. ;
Almeneessier, Aljohara S. ;
BaHammam, Ahmed S. .
FRONTIERS IN ENDOCRINOLOGY, 2021, 12
[5]   Options for Controlling Type 2 Diabetes during Ramadan [J].
Almalki, Mussa H. ;
Alshahrani, Fahad .
FRONTIERS IN ENDOCRINOLOGY, 2016, 7
[6]  
[Anonymous], SURAT AL BAQARAH, V2, P185
[7]   Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial [J].
Azar, S. T. ;
Echtay, A. ;
Bebakar, W. M. Wan ;
Al Araj, S. ;
Berrah, A. ;
Omar, M. ;
Mutha, A. ;
Tornoe, K. ;
Kaltoft, M. S. ;
Shehadeh, N. .
DIABETES OBESITY & METABOLISM, 2016, 18 (10) :1025-1033
[8]   Multi-country retrospective observational study of the management and outcomes of patients with Type 2 diabetes during Ramadan in 2010 (CREED) [J].
Babineaux, S. M. ;
Toaima, D. ;
Boye, K. S. ;
Zagar, A. ;
Tahbaz, A. ;
Jabbar, A. ;
Hassanein, M. .
DIABETIC MEDICINE, 2015, 32 (06) :819-828
[9]  
Bashir Mir Iftikhar, 2012, Indian J Endocrinol Metab, V16, P503, DOI 10.4103/2230-8210.97994
[10]   Safety and tolerability of sodium-glucose co-transporter -2 inhibitors (SGLT-2i) during Ramadan fasting [J].
Eid, Elsayed A. ;
Hussein, Abdelaziz M. ;
Ghazy, Hossam A. .
CLINICAL DIABETOLOGY, 2021, 10 (05) :389-393